Sarcoma
(Jan 2004)
A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)
Haralabos P. Kalofonos,
Charalabos Kourousis,
Michalis V. Karamouzis,
Gregoris Iconomou,
Ekaterini Tsiata,
Fotis Tzorzidis,
Panagiotis Megas,
Elias Lambiris,
Vasilios Georgoulias
Affiliations
Haralabos P. Kalofonos
Division of Oncology, Department of Medicine University Hospital, Patras Medical School, Rion 26504, Greece
Charalabos Kourousis
Department of Medical Oncology, School of Medicine, University General Hospital of Heraclion, Crete, Greece
Michalis V. Karamouzis
Division of Oncology, Department of Medicine University Hospital, Patras Medical School, Rion 26504, Greece
Gregoris Iconomou
Division of Oncology, Department of Medicine University Hospital, Patras Medical School, Rion 26504, Greece
Ekaterini Tsiata
Division of Oncology, Department of Medicine University Hospital, Patras Medical School, Rion 26504, Greece
Fotis Tzorzidis
Division of Oncology, Department of Medicine University Hospital, Patras Medical School, Rion 26504, Greece
Panagiotis Megas
Division of Oncology, Department of Medicine University Hospital, Patras Medical School, Rion 26504, Greece
Elias Lambiris
Department of Orthopedics, University Hospital, Patras Medical School, Rion, Greece
Vasilios Georgoulias
Department of Medical Oncology, School of Medicine, University General Hospital of Heraclion, Crete, Greece
DOI
https://doi.org/10.1155/2004/573035
Journal volume & issue
Vol. 8,
no. 4
Abstract
Read online
Purpose: The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-line chemotherapy in patients with locally advanced and/or metastatic adult STS.
WeChat QR code
Close
